CAS key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Department of Microbiology, The University of Hong Kong, Hong Kong, China.
Sci Rep. 2016 Oct 4;6:34827. doi: 10.1038/srep34827.
Macrophage-mediated innate immune responses play crucial roles in host defense against pathogens. Recent years have seen an explosion of host proteins that act as restriction factors blocking viral replication in infected cells. However, the essential factors restricting Mycobacterium tuberculosis (Mtb) and their regulatory roles during mycobacterial infection remain largely unknown. We previously reported that Mtb tyrosine phosphatase PtpA, a secreted effector protein required for intracellular survival of Mtb, inhibits innate immunity by co-opting the host ubiquitin system. Here, we identified a new PtpA-interacting host protein TRIM27, which is reported to possess a conserved RING domain and usually acts as an E3 ubiquitin ligase that interferes with various cellular processes. We further demonstrated that TRIM27 restricts survival of mycobacteria in macrophages by promoting innate immune responses and cell apoptosis. Interestingly, Mtb PtpA could antagonize TRIM27-promoted JNK/p38 MAPK pathway activation and cell apoptosis through competitively binding to the RING domain of TRIM27. TRIM27 probably works as a potential restriction factor for Mtb and its function is counteracted by Mtb effector proteins such as PtpA. Our study suggests a potential tuberculosis treatment via targeting of the TRIM27-PtpA interfaces.
巨噬细胞介导的固有免疫反应在宿主防御病原体中发挥着至关重要的作用。近年来,大量的宿主蛋白被发现可以作为限制因子,阻止感染细胞中的病毒复制。然而,限制结核分枝杆菌(Mtb)的基本因素及其在分枝杆菌感染过程中的调节作用在很大程度上仍然未知。我们之前曾报道过,Mtb 酪氨酸磷酸酶 PtpA 是一种分泌的效应蛋白,对于 Mtb 的细胞内生存是必需的,它通过利用宿主泛素系统来抑制固有免疫。在这里,我们鉴定了一种新的 PtpA 相互作用的宿主蛋白 TRIM27,据报道它具有保守的 RING 结构域,通常作为一种 E3 泛素连接酶,干扰各种细胞过程。我们进一步证明,TRIM27 通过促进固有免疫反应和细胞凋亡来限制巨噬细胞中分枝杆菌的存活。有趣的是,Mtb PtpA 可以通过竞争性结合 TRIM27 的 RING 结构域,拮抗 TRIM27 促进的 JNK/p38 MAPK 通路激活和细胞凋亡。TRIM27 可能是 Mtb 的一种潜在限制因子,其功能被 Mtb 效应蛋白如 PtpA 拮抗。我们的研究表明,通过靶向 TRIM27-PtpA 界面,可能为结核病治疗提供一种新策略。